AI, pancreatic cancer and food intolerance
headline wide range of Cellvizio abstracts at gastroenterology’s
largest international meeting
Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor
of Cellvizio®, the multidisciplinary probe and needle-based
confocal laser endomicroscopy (p/nCLE) platform, today announced
the presentation of 9 abstracts supporting Cellvizio® at the
Digestive Disease Week® (DDW) Conference, being held on May 18-21,
2024 in Washington, DC. These abstracts focus on artificial
intelligence, pancreatic cystic lesions and pancreatic cancer, food
intolerance and other gastrointestinal disorders. Studies and
presentations are focused on how the use of Cellvizio® positively
impacts patient management and outcomes.
Members of the Mauna Kea executive team will be present at DDW
and meeting with physicians, industry partners, and societies, and
welcome the opportunity to discuss the Company’s recent
achievements and future opportunities as announced in the recent FY
2023 & Q1 2024 sales press release.
"Each year, DDW brings the entire gastroenterology healthcare
community together, and we are proud to have such a wide range of
independent scientific abstracts and data about Cellvizio on
display, especially in the rapidly developing field of artificial
intelligence,” said Sacha Loiseau, Ph.D., Chairman and Chief
Executive Officer of Mauna Kea Technologies. “Cellvizio's role
in the classification and risk stratification of pancreatic cysts
advances the outlook for the management of patients at risk of
pancreatic cancer. Moreover, our clinical value in food intolerance
identification and management is maturing quickly, setting up the
next big opportunity for Cellvizio.”
Highlighted featured
presentations:
ARTIFICIAL INTELLIGENCE-ASSISTED AUTOMATED PREDICTION OF
ADVANCED NEOPLASIA IN IPMNS: A FUNCTIONAL MODEL Sunday, May 19,
10:32am-10:39am Session 3290 Presenting author: Dr. Erica Park, The
Ohio State University Wexner Medical Center
CONFOCAL LASER ENDOMICROSCOPY WITH FOOD ALLERGY SENSITIVITY
TESTING TO DETECT ATYPICAL FOOD ALLERGIES IN PEDIATRIC PATIENTS
WITH CHRONIC ABDOMINAL PAIN AND IRRITABLE BOWEL SYNDROME
Tuesday, May 21, 8:11am-8:18am Session 5145 Presenting author: Dr.
Clifton Huang, Cook Children’s Health Care System
ACCURACY OF REAL-TIME EUS-GUIDED CONFOCAL LASER
ENDOMICROSCOPY INTERPRETATION FOR DISCERNING SPECIFIC TYPES OF
PANCREATIC CYSTIC LESIONS: INSIGHTS FROM A MULTICENTER PROSPECTIVE
STUDY Tuesday, May 21, 10:15am-10:30am Session 5260 Presenting
author: Dr. Jordan Burlen, The Ohio State University Wexner Medical
Center
Featured poster sessions:
THE ROLE OF CONFOCAL ENDOMICROSCOPY FOR THE DIAGNOSIS OF
GASTRIC ANTRAL VASCULAR ECTASIA Saturday, May 18,
12:30pm-1:30pm Session 6325 Presenting author: Dr. Navkiran
Randhawa, Franciscan Health
IMPROVING PRE-SURGICAL RISK STRATIFICATION THROUGH
EUS-CONFOCAL ENDOMICROSCOPY: INSIGHTS FROM AN INTEROBSERVER
AGREEMENT STUDY AMONG PANCREATICOBILIARY PATHOLOGISTS IN THE
CLASSIFICATION OF DYSPLASIA FOR IPMNS Monday, May 20,
12:30pm-1:30pm Session 8165 Presenting author: Dr. Matthew Leupold,
The Ohio State University Wexner Medical Center
COMPARISON OF DIAGNOSTIC ACCURACY OF ENDOCYTOSCOPY AND
PROBE-BASED CONFOCAL LASER ENDOMICROSCOPY Monday, May 20,
12:30pm-1:30pm Session 8390 Presenting author: Dr. Ah Young Lee,
CHA Gangnam Medical Center
PRE-OPERATIVE RISK STRATIFICATION OF IPMNS USING FUKUOKA
GUIDELINES AND CONFOCAL ENDOMICROSCOPY IMAGING Monday, May 21,
12:30pm-1:30pm Session 9255 Presenting author: Dr. Matthew Leupold,
The Ohio State University Wexner Medical Center
ASSOCIATIONS BETWEEN PREOPERATIVE ENDOSCOPIC
ULTRASOUND-GUIDED CONFOCAL LASER ENDOMICROSCOPY (EUS-CLE) AND
HISTOLOGICAL SUBTYPE OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS
(IPMN) Monday, May 21, 12:30pm-1:30pm Session 9240 Presenting
author: Dr. Bryn Koehler, The Ohio State University Wexner Medical
Center
FOOD-INDUCED INTESTINAL MUCOSAL REACTIONS IN IRRITABLE BOWEL
SYNDROME DETECTED WITH CONFOCAL LASER ENDOMICROSCOPY Monday,
May 21, 12:30pm-1:30pm Session 9345 Presenting author: Dr. Amanda
Blomsten, University of Gothenburg
***
About Digestive Disease Week® Digestive Disease Week®
(DDW) is the largest international gathering of physicians,
researchers and academics in the fields of gastroenterology,
hepatology, endoscopy and gastrointestinal surgery. Jointly
sponsored by the American Association for the Study of Liver
Diseases (AASLD), the American Gastroenterological Association
(AGA), the American Society for Gastrointestinal Endoscopy (ASGE)
and the Society for Surgery of the Alimentary Tract (SSAT), DDW is
an in-person and online meeting from May 18-21, 2024. The meeting
showcases more than 5,600 abstracts and hundreds of lectures on the
latest advances in GI research, medicine and technology. More
information can be found at www.ddw.org.
About Mauna Kea Technologies Mauna Kea Technologies is a
global medical device company that manufactures and sells
Cellvizio®, the real-time in vivo cellular imaging platform. This
technology uniquely delivers in vivo cellular visualization which
enables physicians to monitor the progression of disease over time,
assess point-in-time reactions as they happen in real time,
classify indeterminate areas of concern, and guide surgical
interventions. The Cellvizio® platform is used globally across a
wide range of medical specialties and is making a transformative
change in the way physicians diagnose and treat patients. For more
information, visit www.maunakeatech.com.
Disclaimer This press release contains forward-looking
statements about Mauna Kea Technologies and its business. All
statements other than statements of historical fact included in
this press release, including, but not limited to, statements
regarding Mauna Kea Technologies' financial condition, business,
strategies, plans and objectives for future operations are
forward-looking statements. Mauna Kea Technologies believes that
these forward-looking statements are based on reasonable
assumptions. However, no assurance can be given that the
expectations expressed in these forward-looking statements will be
achieved. These forward-looking statements are subject to numerous
risks and uncertainties, including those described in Chapter 2 of
Mauna Kea Technologies' 2023 Annual Report filed with the Autorité
des marchés financiers (AMF) on April 30, 2024, which is available
on the Company's website (www.maunakeatech.fr), as well as the
risks associated with changes in economic conditions, financial
markets and the markets in which Mauna Kea Technologies operates.
The forward-looking statements contained in this press release are
also subject to risks that are unknown to Mauna Kea Technologies or
that Mauna Kea Technologies does not currently consider material.
The occurrence of some or all of these risks could cause the actual
results, financial condition, performance or achievements of Mauna
Kea Technologies to differ materially from those expressed in the
forward-looking statements. This press release and the information
contained herein do not constitute an offer to sell or subscribe
for, or the solicitation of an order to buy or subscribe for,
shares of Mauna Kea Technologies in any jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such
jurisdiction. The distribution of this press release may be
restricted in certain jurisdictions by local law. Persons into
whose possession this document comes are required to comply with
all local regulations applicable to this document.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240506513693/en/
Mauna Kea Technologies investors@maunakeatech.com
NewCap - Investor Relations Aurélie Manavarere / Thomas
Grojean +33 (0)1 44 71 94 94 maunakea@newcap.eu
Grafico Azioni Mauna Kea Technologies (EU:ALMKT)
Storico
Da Feb 2025 a Mar 2025
Grafico Azioni Mauna Kea Technologies (EU:ALMKT)
Storico
Da Mar 2024 a Mar 2025
